Methotrexate (high-dose)
Trexall · Antifolate
Crystal nephropathy; glucarpidase rescue.
XTALATN
ModerateOpen →
Anti-CD20 antibody
Obinutuzumab
Gazyva · Obinu
A glycoengineered type II anti-CD20 antibody with the highest tumor-lysis risk among CD20 agents in CLL.
ModerateAnti-CD20 antibody (type II) · approved 2013
CLL/SLLFollicular lymphoma
Signature kidney injury
Crystal / Obstructive Nephropathy
Carries a notably high tumor-lysis risk in CLL — among the highest of the anti-CD20 agents — particularly with the first (split) infusion in high-burden disease (the CLL11 trial enrolled patients with CrCl 30–69 mL/min and saw higher infusion reactions/TLS). Direct nephrotoxicity is case-level.
Source: Goede et al., NEJM 2014 (CLL11)
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityModerate
ReversibilityPartially reversible
Evidence0 refs
Nephron map
Vasculature / Endothelium
Proximal Tubule
Distal Tubule / Collecting Duct
Tubular LumenThe urine flow path
Crystal / Obstructive Nephropathy
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Mechanism of kidney injury
More potent, rapid B-cell killing (enhanced direct death plus ADCC) releases uric acid and phosphate faster than rituximab; intratubular uric acid and calcium-phosphate crystals cause obstruction (crystal nephropathy) with urate-driven vasoconstriction and ischemic ATN — tumor-lysis AKI. In-vitro, CD20 antibodies kill within 12–24 h, explaining first-infusion TLS.
Clinical presentation
Tumor-lysis labs (hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia) and rising creatinine, especially around the first infusion; pronounced infusion-related reactions (concentrated at the first infusion); occasional thrombocytopenia.
Onset
Acute — within hours to days of the first (split) dose.
Reversibility
Partially reversible
Anticancer mechanism
Glycoengineered (afucosylated) type II humanized anti-CD20 IgG1 monoclonal antibody. Type II binding produces greater direct (non-apoptotic) cell death and, through afucosylation, markedly enhanced antibody-dependent cellular cytotoxicity (ADCC) versus rituximab, used in CLL and follicular lymphoma.
Management
IV hydration, rasburicase, electrolyte correction; hold therapy and provide renal replacement therapy if severe (lower threshold given ongoing lysis).
Risk factors
- High circulating lymphocyte count / bulky CLL
- Elevated LDH
- Pre-existing CKD (CLL11 enrolled CrCl 30–69)
- Volume depletion
Prevention
- Split first-dose administration (day 1: 100 mg, day 2: 900 mg)
- Aggressive TLS prophylaxis (hydration plus rasburicase or allopurinol)
- Close laboratory monitoring at the first cycle
- Pre-medication for infusion reactions
Note · TLS prophylaxis is mandatory in high-risk CLL; renal injury is tumor-lysis-mediated rather than a direct antibody effect. Its greater potency over rituximab also means a higher TLS/infusion-reaction burden.
Clinical depth
Renal dose adjustment
No renal dose adjustment; antibody clearance is target-mediated/reticuloendothelial, not renal. CLL11 specifically included patients with CrCl 30–69 mL/min, supporting use in moderate renal impairment with appropriate TLS precautions.
Dialyzability & ESKD dosing
Not dialyzed — a large IgG1 antibody not removed by HD/PD; usable in ESKD at standard dosing. Dialysis treats TLS complications, not drug levels.
Differential diagnosis
Tumor-lysis crystal nephropathy (early, first-infusion, urate/phosphate profile) vs infusion-reaction hypotension causing prerenal AKI vs CLL-intrinsic kidney disease. The split-dose first-infusion timing of TLS is characteristic.
Monitoring
- TLS panel before and after the first (split) infusion and through the first cycle
- Volume status and urine output during the first infusions
- Infusion-reaction monitoring (highest risk at first infusion)
Key trials & series
- Goede et al., NEJM 2014 — CLL11 registrational trial (obinutuzumab-chlorambucil superior to rituximab-chlorambucil; enrolled renally impaired patients; higher infusion/TLS risk)
Clinical pearls
- Obinutuzumab has the highest TLS risk of the anti-CD20 agents — the split first dose and rasburicase prophylaxis are essential.
- CLL11 deliberately enrolled patients with CrCl 30–69, so it is usable in moderate CKD with full TLS precautions.
- Greater potency than rituximab means more infusion reactions and faster tumor lysis — front-load monitoring at the first infusion.
Where it strikes
Nephron segments
Tubular Lumen
The urine flow path
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Crystal / Obstructive NephropathyAcute Tubular NecrosisPrerenal / Hemodynamic AKIElectrolyte Wasting
Evidence
7 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkObinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.Goede V et al. · N Engl J Med 2014 · PMID 24401022CLL11 registrational trial; enrolled renally impaired patients with higher infusion-reaction/TLS risk; superior to rituximab.PMIDDirect Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis.Constantinides M et al. · Cancers (Basel) 2023 · PMID 36831451Mechanism for obinutuzumab's rapid, high TLS risk (greater direct killing than rituximab).PMIDExpert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel.Perissinotti AJ et al. · Cancer Treat Rev 2023 · PMID 37579533Updated TLS guideline accounting for high-risk agents (obinutuzumab/venetoclax) and renal management.PMIDGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.Coiffier B et al. · J Clin Oncol 2008 · PMID 18509186Foundational TLS prophylaxis/renal framework.PMIDRenal involvement in chronic lymphocytic leukemia.Wanchoo R et al. · Clin Kidney J 2018 · PMID 30288263Onconephrology review citing obinutuzumab as an important tumor-lysis nephrotoxicity in CLL.PMIDObinutuzumab-induced severe acute thrombocytopenia: a case report and literature review.Kou K et al. · Front Immunol 2025 · PMID 40918110Reviews obinutuzumab adverse effects, including tumor lysis syndrome.PMIDEmergencies in Hematology: Why, When and How I Treat?Duminuco A et al. · J Clin Med 2024 · PMID 39768494Tumor lysis syndrome pathophysiology and AKI management.